5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)
    Meeting Abstract

    Smith, M. R.; Sweeney, C.; Rathkopf, D. E.; Scher, H. I.; Logothetis, C.; George, D. J.; Higano, C. S.; Yu, E. Y.; Harzstark, A. L.; Small, E. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR plus T cells
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Olszewska, M.; Taylor, C.; Bartido, S.; Scher, H. I.; Sadelain, M.; Riviere, I.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer
    Meeting Abstract

    Oh, W. K.; Kantoff, P.; Scher, H. I.; Magidson, J.; Wassmann, K.; Lee, G. S. M.; Katz, L. M.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Bjarnason, G. A.; Szcylik, C.; Rha, S. Y.; Esteban, E.; De Giorgi, U.; MacKenzie, M. J.; Mainwaring, P. N.; North, S.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial
    Meeting Abstract

    Motzer, R. J.; Nosov, D.; Eisen, T.; Bondarenko, I. N.; Lesovoy, V.; Lipatov, O. N.; Tomczak, P.; Lyulko, A. A.; Alyasova, A.; Harza, M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Treatment of refractory metastatic renal cell carcinoma (RCC) with lenvatinib (E7080) and everolimus
    Meeting Abstract

    Molina, A. M.; Motzer, R. J.; Hutson, T. E.; Larkin, J. M. G.; Gold, A.; Andresen, C.; Wood, K.; Michaelson, M. D.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases
    Meeting Abstract

    Morris, M. J.; Hammers, H. J.; Sweeney, C.; Bloma, M.; Aksnes, A. K.; O'Bryan-Tear, C. G.; Carrasquillo, J. A.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save